• Home
  • Resource Library

Resource Library

publications • bibliographies • white papers

All Publications

  • Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohortsAbstract

    BACKGROUND: Preclinical studies have demonstrated that propranolol inhibits several pathways involved in breast cancer progression and metastasis. We investigated whether breast cancer patients who used propranolol, or other non-selective beta-blocers, had reduced breast cancer-specific or all-cause mortality in eight European cohorts

    Cardwell CR, Pottegard A, Vaes E, Garmo H, Murray LJ, Brown C, Vissers PA, O'Rorke M, Visvan athan K, Cronin-Fenton D, DeSchutter H, Lambe M, Powe DG, van Herk-Sukel MP, Gavin A, Friis S, Sharp L, Bennett K. Breast Cancer Res. 2016 Dec 01; 18 (1): 119.
  • Asthma related medication use and exacerbations in children and adolescents with type 1 diabetesAbstract

    OBJECTIVES: To investigate the use of asthma medication and occurrence of asthma exacerbations up to 5 years before and after the onset of type 1 diabetes mellitus (T1DM) in children and adolescents. METHODS: Children and adolescents younger than 1years with at least 2 insulin prescriptions between 1999 and 2009 classified as T1DM cohort (n = 915) and a 4 times larger reference cohort (n = 3,590) with the same age and gender were identified from the Dutch PHARMO Record Linkage System

    Ahmadizar F, Souverein PC, Arets HG, deBoer A, Maitland-van der Zee AH. Pediatr Pulmonol. 2016 Nov; 51 (11): 1113-1121.
  • Drug dispensings among elderly in the year before colon cancer diagnosis versus matched cancer-free controlsAbstract

    WHAT IS KNOWN AND OBJECTIVE: The concomitant use of multiple drugs is common among the general population of elderly. The aim of this study was to provide an overview of which drugs are dispensed to elderly in the year before colon cancer diagnosisand to compare this with cancer-free controls. METHODS: Data from the Eindhoven Cancer Registry were linked to the PHARMO Database Network

    van Erning FN, Zander s MM, Kuiper JG, van Herk-Sukel MP, Maas HA, Vingerhoets RW, Zimmerman DD, deFeyter EP, van dePoll ME, Lemmens VE. J Clin Pharm Ther. 2016 Oct; 41 (5): 538-45.
  • Cardiovascular medication use and cardiovascular disease in children and adolescents with type 1 diabetes: a population-based cohort studyAbstract

    OBJECTIVES: To investigate the 5-yr prevalence and incidence rates of cardiovascular medication and cardiovascular disease before and after onset of type 1 diabetes (T1D) in children and adolescents. METHODS: Children and adolescents (<19 yr) with1D (n = 925), defined as those who received at least two insulin prescriptions, and a four times larger reference cohort (n = 3591) with the same age and gender in the Dutch PHARMO Record Linkage System (RLS) were studied in a retrospective cohort studybetween 1999 and 2009

    Ahmadizar F, FazeliFarsani S, Souverein PC, van der Vorst MM, deBoer A, Maitland-van der Zee AH. Pediatr Diabetes. 2016 Sep; 17 (6): 433-40.
  • Prescribing pattern of antipsychotic drugs during the years 1996-2010: a population-based database study in Europe with a focus on torsadogenic drugsAbstract

    INTRODUCTION: Antipsychotic drugs (APDs) are used to treat several mental illnesses. Some APDs have long been known to be associated with QT prolongation, potentially leading to torsades de pointes (TdP) and sudden cardiac death (SCD). In 2005, thiridazine was withdrawn because of the risk of SCD, bringing further attention to the arrhythmogenic potential of APDs

    Oteri A, Mazzaglia G, Pecchioli S, Molokhia M, Ulrichsen SP, Peder sen L, Poluzzi E, DePonti F, Garbe E, Schink T, Herings R, Bezemer ID, Sturkenboom MC, Trifiro G. Br J Clin Pharmacol. 2016 Aug; 82 (2): 487-97.
  • Post authorization safety study comparing quetiapine to risperidone and olanzapineAbstract

    OBJECTIVES: To compare rates of specific adverse outcomes between patients starting quetiapine, olanzapine, or risperidone use in the Netherlands. METHODS: Observational study using the PHARMO Database Network, including patients starting quetiapin(4658), olanzapine (5856), or risperidone (7229) in 2000-2009, comparing rates of all-cause mortality, failed suicide attempts, extrapyrimidal symptoms (EPS), diabetes mellitus (DM), hypothyroidism, and acute myocardial infarction (AMI)

    Heintjes EM, Overbeek JA, Penning-van Beest FJ, Brobert G, Herings RM. Hum Psychopharmacol. 2016 Jul; 31 (4): 304-12.
  • Prescription behavior for gastroprotective drugs in new users as a result of communications regarding clopidogrel-proton pump inhibitor interactionAbstract

    Safety concerns of the concomitant use of clopidogrel-proton pump inhibitors (PPIs) were published in 2009 and 2010 by the medicines regulatory agencies, including a direct healthcare professional communication. We examined the association between various safety statements and prescription behavior for gastroprotective drugs in naive patients in the Netherlands during the years 2008-2011

    Pharmacology Research & Perspectives. July 18; 4 (4): e00242.
  • Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control studyAbstract

    Analyses of healthcare data from 30 million individuals in three countries showed that current use of bisphosphonates may be associated with a small increased risk of cardiac valvulopathy (vs. those not exposed within the previous year), although cnfounding cannot be entirely ruled out. The observed tendency for decreased valvulopathy risk with cumulative duration of bisphosphonate use >6 months may even indicate a protective effect with prolonged use

    Coloma PM, deRidder M, Bezemer I, Herings RM, Gini R, Pecchioli S, Scotti L, Rijnbeek P, Mosseveld M, van der Lei J, Trifiro G, Sturkenboom M, Consortium Eu-Adr. Osteoporos Int. 2016 May; 27 (5): 1857-67.
  • Musculoskeletal Hospital Admission and Surgical Procedure Rates among Patients Treated for Rheumatoid Arthritis in the Netherlands 1999-2012Abstract

    Objectives: To assess trends in hospitalizations among patients receiving rheumatoid arthritis (RA)-treatment in a 13-year period compared with population references.

    Bezemer ID, Kool-Houweling LMA, Alemao E, Penning-van Beest FJA, Herings RMC. J Orthopedics Rheumatol. 2016 April; 3 (1):
  • The effect of aspirin and nonsteroidal anti-inflammatory drug use after diagnosis on survival of oesophageal cancer patientsAbstract

    BACKGROUND: Aspirin use has been shown to lower incidence and mortality in cancer patients. The aim of this population-based study was to determine the effect of postdiagnosis low-dose aspirin use on survival of patients with oesophageal cancer. MEHODS: Patients with oesophageal cancer (1998-2010) were selected from the Eindhoven Cancer Registry and linked with outpatient pharmacy data regarding aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs)

    van Staalduinen J, Frouws M, Reimers M, Bastiaannet E, van Herk-Sukel MP, Lemmens V, de Steur WO, Hartgrink HH, van de Velde CJ, Liefers GJ. Br J Cancer. 2016 Apr 26; 114 (9): 1053-9.